Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up [0.03%]
成人髓系肿瘤易感的遗传倾向 Nordic指南：基因诊断、临床管理和随访建议
Panagiotis Baliakas,Bianca Tesi,Ulla Wartiovaara-Kautto et al.
Panagiotis Baliakas et al.
Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased...
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study [0.03%]
一项罕见病患者的真实世界多中心观察性研究的成果：伊萨康唑在血液科病人中的应用
Chiara Cattaneo,Alessandro Busca,Doriana Gramegna et al.
Chiara Cattaneo et al.
Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of the new azole isavuconazole (ISV) in a clinical care setting, we planned a multicenter re...
Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group [0.03%]
儿童急性髓系白血病小于2岁儿童的急性髓细胞 leukemia是否为一个特异实体？来自法国ELAL02研究小组的报告
S Blais,H Boutroux,M Pasquet et al.
S Blais et al.
The clinical and biological characteristics of children under 2 years (infants) with acute myeloid leukemia (AML) are different from those of older children. We aimed to describe the specific characteristics of this population and the poten...
There is a Scientific Need for the Right Leukemia-Lymphoma Cell Lines [0.03%]
建立适合的白血病及淋巴瘤细胞系以满足科研需求
Hans G Drexler,Sonja Eberth,Stefan Nagel et al.
Hans G Drexler et al.
Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies [0.03%]
输血依赖与非输血依赖低危MDS患者的贫血治疗：现有哪些策略及未来展望
Ulrich Germing,Ester N Oliva,Devendra Hiwase et al.
Ulrich Germing et al.
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders with a highly diverse clinical course. For lower-risk MDS patients, therapeutic objectives aim to correct chronic anemia and improve/maintain health-related ...
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors [0.03%]
T-ALL中jak/stat信号通路突变(包括STAT5B N642H突变)对jak1/jak3抑制剂敏感性研究
Inge Govaerts,Kris Jacobs,Roel Vandepoel et al.
Inge Govaerts et al.
Melania Tesio
Melania Tesio
Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia [0.03%]
Janus激酶抑制剂鲁索利替尼联合地塞米松治疗T细胞急性淋巴细胞白血病的体内体外研究
Delphine Verbeke,Olga Gielen,Kris Jacobs et al.
Delphine Verbeke et al.
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling [0.03%]
体外通过适当的活化信号可以克服慢性淋巴细胞白血病中小天然杀伤细胞的低反应性
Tom Hofland,Sanne Endstra,Calum K P Gomes et al.
Tom Hofland et al.
Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction, which may underlie the hampered efficacy of cellular immunotherapy. Most data on dampened immune responses in CLL come from studies investigating CLL and...
Fleur S Kleijwegt,Afnan Abdul Roda,José Rolvink et al.
Fleur S Kleijwegt et al.
Case Reports
HemaSphere. 2019 Oct 22;3(6):e307. DOI:10.1097/HS9.0000000000000307 2019